ROCHESTER, N.Y., Aug. 28, 2013 /PRNewswire/ -- Lucid, Inc. (OTBB: LCDX), d/b/a Caliber Imaging & Diagnostics (Caliber I.D.), a leader in noninvasive optical biopsies of skin and manufacturer of VivaScope® confocal imaging systems, has entered into a strategic advisory agreement with H.C. Wainwright & Co., LLC, designed to benefit the growth of Caliber I.D. as it continues to develop its business through a variety of channels.
As part of the agreement, H.C. Wainwright will serve as an advisor to Caliber I.D. by helping to identify, originate and develop potential strategic partnerships, assisting with M&A transactions, and helping to raise capital. The agreement additionally includes but is not limited to new product procurement, generating additional distribution channels and assessing collaborations to promote Caliber I.D.'s business.
Caliber I.D.'s current integrated platform of VivaScope® products includes non-invasive cellular imaging systems that enable physicians to diagnose skin disease, including basal cell carcinoma, melanoma, and inflammatory disorders, in realtime with an optical biopsy as compared with a traditional invasive or surgical biopsy. Additional applications of the technology include therapeutic monitoring, claims validation for cosmeceuticals and pharmaceuticals, and intrasurgical imaging of living tissues.
Additional information regarding this agreement can be found in Caliber Imaging & Diagnostics' Form 8-K filed with the Securities and Exchange Commission on August 27, 2013.
About Caliber Imaging & Diagnostics
Caliber Imaging & Diagnostics' platform of products offer increased productivity from the research laboratory to the doctor's office or the surgeon's operating room. Caliber I.D.'s platform of products provide precise accuracy, consistent reliability, and online backup that all combine to lead to better patient care. For more information about Caliber I.D. and its products, please visit www.caliberid.com.
VivaScope® is a registered trademark of Caliber Imaging & Diagnostics.
About H.C. Wainwright & Co., LLC
H. C. Wainwright & Co., LLC is an investment bank dedicated to providing corporate finance, strategic advisory and related services to public and private growth companies across multiple sectors and regions. The H. C. Wainwright team has been the leader in the PIPE (private investment in public equity) and RD (registered direct offering) transaction markets. According to Sagient Research Systems, the team has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD transactions cumulatively since 1998. H. C. Wainwright was established in 1868 and is headquartered in New York City.
This press release contains "forward looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to our plans, objectives, expectations and intentions and other statements that contain words such as "expects," "contemplates," "anticipates," "plans," "intends," "believes," "assumes" and variations of such words or similar expressions that predict or indicate future events or trends, or that do not relate to historical matters. These statements are based on our current beliefs or expectations and are inherently subject to significant known and unknown uncertainties and changes in circumstances, many of which are beyond our control. There can be no assurance that our beliefs or expectations will be achieved and actual results may differ materially from our beliefs or expectations due to financial, economic, business, regulatory and other factors or conditions affecting us or our industry in general, as well as more specific risks and uncertainties facing us, such as those set forth in the Risk Factors section of the Forms 10-Q and 10-K filed by us with the Securities and Exchange Commission.
Chief Financial Officer
|SOURCE Caliber Imaging & Diagnostics|
Copyright©2012 PR Newswire.
All rights reserved